View All Blog Posts

Healthy Innovation Statement on COVID-19

Our thoughts are with those affected by the outbreak of COVID-19, the novel strain of the coronavirus, both here in Southeast Asia and around the globe. Addressing the global public health challenges presented by COVID-19 will require collaboration and partnership from stakeholders across the globe. Working together, governments, global health authorities and the private sector can develop solutions to diagnose, treat and prevent the further spread of COVID-19. Now, as always, policies that advance the benefits of healthy innovation are vital to solving public health crises.

For more information about how the industry is responding to the coronavirus crisis, please visit the International Federation of Pharmaceutical Manufacturers and Associations and the Pharmaceutical Research and Manufacturers of America.

Recent Blog Posts

What They Are Saying: IP Protections Critical to Combatting COVID-19 in Southeast Asia

The global biopharmaceutical industry relies on strong intellectual property (IP) rights to promote the development of breakthrough treatments and cures for patients. Innovation, underpinned by reliable IP protections, is now more important than ever as the private sector works around the clock to develop solutions to help prevent infection and treat patients with COVID-19, a

World Health Assembly: Intellectual Property in the SEA Region

The World Health Assembly (WHA) is being held virtually this week, including delegations from 194 World Health Organization member states. These officials will discuss the world’s response to the COVID-19 pandemic and determine the priorities of the Organization for the year ahead.